Shop
Showing 1–12 of 200 results
This content outlines the significant issues in medical research initiated by the Millennium Project, emphasizing the contributions of Sysmex in addressing these challenges through its advanced technologies and solutions.
Important Issues in Medical Research Initiated by the Millennium Project
1. Recent advance in the diagnosis and treatment of paroxysmal nocturnal hemoglobinuria (PNH)
Read moreDiscussion on the recent progress in the pathogenesis, diagnosis and treatment of Paroxysmal nocturnal hemoglobinuria (PNH).
Professor Yuzuru KANAKURA, M.D., Ph.D. The Department of Hematology and Oncology, Osaka University Graduate School of Medicine
This content outlines the significance of CAR-T cell therapy in gene therapy, highlighting the advancements in the field and emphasizing the contributions of Sysmex's technologies in supporting CAR-T cell research and clinical applications.
Gene Therapy Comes of Age: Focusing on CAR-T Cell Therapy
Introduction of a research findings of JAK2V617F, CALR, and MPL mutations in patients suspected of Philadelphia-negative myeloproliferative neoplasm (MPN), as well as discussion on surrounding issues.
Professor Norio KOMATSU, M.D., Ph.D. Department of Hematology, Juntendo University School of Medicine
Summary of major advances of recent years in the field of MDS research, focusing on the results of the studies by Prof. Ogawa’s team.
Professor Seishi OGAWA, M.D., Ph.D.,Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
This content outlines the historical development, current advancements, and future directions of regulatory T cell research and emphasizes the role of Sysmex's technologies in supporting this innovative field.
Sysmex, a leader in healthcare technology, supports this field with advanced tools and technologies for studying and manipulating Tregs, facilitating research and clinical applications.
Introduction of a study investigating a possible causative gene defect in the large Japanese family with inherited thrombophilia, as well as the discovery of a novel missense mutation in the prothombin gene (p.ARG596Leu) resulting in a variant prothrombin.
Professor Tetsuhito KOJIMA, M.D., Ph, D.Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine
This content highlights the potential of cell-based therapy for Parkinson’s disease, emphasizing the role of Sysmex's technologies in supporting research and clinical applications in this innovative field.
Cell-Based Therapy for Parkinson’s Disease: Innovations and Insights from Sysmex
An overview of the recent progress and vision in the treatment of hemophilia including clinical trials on therapeutic drugs and gene therapy.
Professor Midori SHIMA, M.D., Ph, D.Department of Pediatrics, Nara Medical University
This content highlights the significance of iPS cells in retinal regenerative medicine and emphasizes the contributions of Sysmex in advancing this innovative field through its technologies and solutions.
Retinal Regenerative Medicine Using iPS Cells: Innovations and Insights from Sysmex
A Single Tube 10-Color Flow Cytometry Assay Optimizes Detection of Minimal Residual Disease in Chronic Lymphocytic Leukemia
Read moreSartor MM, Gottlieb DJ.Sartor MM, Gottlieb DJ., Cytometry B Clinical Cytometry 2013; 84B: 96-103
